

Andrew M Lowy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5796581/publications.pdf>

Version: 2024-02-01

82
papers

6,397
citations

134610

34
h-index

78623

77
g-index

84
all docs

84
docs citations

84
times ranked

11265
citing authors

#	ARTICLE	IF	CITATIONS
1	Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. <i>In Vivo</i> , 2022, 36, 57-62.	0.6	5
2	Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. <i>Gut and Liver</i> , 2022, 16, 625-636.	1.4	6
3	The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 2037.	1.7	7
4	Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. <i>Oncogene</i> , 2021, 40, 1957-1973.	2.6	22
5	Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1716-1723.	0.8	5
6	Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness. <i>Cancer Discovery</i> , 2021, 11, 1808-1825.	7.7	53
7	Tumor-penetrating therapy for $\alpha 5$ integrin-rich pancreas cancer. <i>Nature Communications</i> , 2021, 12, 1541.	5.8	37
8	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2021, 7, 421.	3.4	159
9	Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 279-287.	1.0	20
10	Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. <i>Cancer Cell</i> , 2021, 39, 678-693.e11.	7.7	91
11	Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal Origin. <i>JCO Precision Oncology</i> , 2021, 5, 1069-1072.	1.5	1
12	Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC. <i>Human Pathology</i> , 2021, 113, 104-110.	1.1	3
13	Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1003-1012.	0.4	21
14	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	3.2	22
15	Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC). <i>BMC Gastroenterology</i> , 2021, 21, 340.	0.8	1
16	Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2469-2482.	1.9	4
17	A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms. <i>Annals of Surgical Oncology</i> , 2021, 28, 4685-4694.	0.7	12
18	A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2100-2110.	3.2	17

#	ARTICLE	IF	CITATIONS
19	Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (<i>g</i> <i>BRCA</i>1/2+) mutations: SWOG S2001.. Journal of Clinical Oncology, 2021, 39, TPS447-TPS447.	0.8	10
20	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	0.7	15
21	Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond. Cancers, 2021, 13, 4991.	1.7	10
22	Association of an acute pain service with postoperative outcomes following pancreaticoduodenectomy. Journal of Perioperative Practice, 2020, 30, 309-314.	0.3	2
23	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 134-146.	0.7	14
24	Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer, 2020, 23, 550-560.	2.7	21
25	Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Annals of Surgical Oncology, 2020, 27, 3259-3267.	0.7	14
26	Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	101
27	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. Journal of Surgical Oncology, 2020, 122, 980-985.	0.8	10
28	Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models. Journal of Visualized Experiments, 2020, , .	0.2	2
29	Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Molecular Cancer Therapeutics, 2020, 19, 157-167.	1.9	21
30	Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. PLoS ONE, 2020, 15, e0243252.	1.1	2
31	Detection and Quantification of GPCR mRNA: An Assessment and Implications of Data from High-Content Methods. ACS Omega, 2019, 4, 17048-17059.	1.6	25
32	Obstruction-Free Survival Following Operative Intervention for Malignant Bowel Obstruction in Appendiceal Cancer. Annals of Surgical Oncology, 2019, 26, 3611-3617.	0.7	2
33	Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2019, 26, 2276-2284.	0.7	15
34	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Annals of Surgical Oncology, 2019, 26, 2234-2240.	0.7	16
35	Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. Annals of Surgical Oncology, 2019, 26, 1421-1427.	0.7	18
36	MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages. Oncogene, 2019, 38, 5599-5611.	2.6	29

#	ARTICLE	IF	CITATIONS
37	A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. <i>Cell</i> , 2019, 177, 572-586.e22.	13.5	107
38	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. <i>Genome Medicine</i> , 2019, 11, 8.	3.6	88
39	Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases. <i>Nature Communications</i> , 2019, 10, 5745.	5.8	45
40	Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. <i>American Journal of Cancer Research</i> , 2019, 9, 390-405.	1.4	7
41	Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC. <i>Annals of Surgical Oncology</i> , 2018, 25, 702-708.	0.7	33
42	Safety and Outcome Measures of First-in-Human Intraperitoneal \pm Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 716-721.	0.6	70
43	Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. <i>Journal of Surgical Research</i> , 2018, 221, 183-189.	0.8	22
44	GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. <i>FASEB Journal</i> , 2018, 32, 1170-1183.	0.2	83
45	Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 91-97.	0.7	22
46	Genomic Landscape of Appendiceal Neoplasms. <i>JCO Precision Oncology</i> , 2018, 2, 1-18.	1.5	23
47	E47 Governs the MYC-CDKN1B/p27 KIP1 -RB Network to Growth Arrest PDA Cells Independent of CDKN2A/p16 INK4A and Wild-Type p53. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 181-198.	2.3	14
48	Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 2400-2408.	0.7	46
49	GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. <i>Frontiers in Pharmacology</i> , 2018, 9, 431.	1.6	103
50	Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients. <i>World Journal of Surgical Oncology</i> , 2018, 16, 87.	0.8	3
51	GPR68, a proton sensing GPCR, mediates interaction of pancreatic cancer associated fibroblasts and cancer cells. <i>FASEB Journal</i> , 2018, 32, 695.2.	0.2	0
52	A Novel Inhibitor that Targets both p53-Dependent Apoptotic and Autophagy Pathways as a Pancreatic Cancer Therapeutic. <i>FASEB Journal</i> , 2018, 32, 836.16.	0.2	0
53	Hyaluronan-binding peptide for targeting peritoneal carcinomatosis. <i>Tumor Biology</i> , 2017, 39, 101042831770162.	0.8	21
54	Molecular Pathways: Targeting the Microenvironment of Liver Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 6390-6399.	3.2	79

#	ARTICLE	IF	CITATIONS
55	Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. <i>PLoS ONE</i> , 2017, 12, e0189051.	1.1	31
56	Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care. <i>PLoS ONE</i> , 2017, 12, e0179216.	1.1	18
57	A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 53154-53167.	0.8	14
58	Macrophage PI3K β Drives Pancreatic Ductal Adenocarcinoma Progression. <i>Cancer Discovery</i> , 2016, 6, 870-885.	7.7	235
59	Urokinase-controlled tumor penetrating peptide. <i>Journal of Controlled Release</i> , 2016, 232, 188-195.	4.8	46
60	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2016, 151, e161137.	2.2	365
61	FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. <i>BMC Cancer</i> , 2016, 16, 24.	1.1	44
62	Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. <i>Nature</i> , 2016, 534, 407-411.	13.7	114
63	A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 1609-1617.	0.7	37
64	Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. <i>Oncotarget</i> , 2016, 7, 45959-45975.	0.8	24
65	PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. <i>Oncotarget</i> , 2016, 7, 28218-28234.	0.8	25
66	A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. <i>Journal of Controlled Release</i> , 2015, 212, 59-69.	4.8	62
67	Tumor Radiosensitization by Monomethyl Auristatin E: Mechanism of Action and Targeted Delivery. <i>Cancer Research</i> , 2015, 75, 1376-1387.	0.4	53
68	Tumor-Penetrating iRGD Peptide Inhibits Metastasis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 120-128.	1.9	99
69	Borderline resectable pancreatic cancer: Definitions and management. <i>World Journal of Gastroenterology</i> , 2014, 20, 10740.	1.4	135
70	A Hypusine ϵ -eIF5A ϵ -PEAK1 Switch Regulates the Pathogenesis of Pancreatic Cancer. <i>Cancer Research</i> , 2014, 74, 6671-6681.	0.4	80
71	Improved Perioperative Outcomes With Minimally Invasive Distal Pancreatectomy. <i>JAMA Surgery</i> , 2014, 149, 237.	2.2	81
72	A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. <i>Nature Medicine</i> , 2014, 20, 1340-1347.	15.2	188

#	ARTICLE	IF	CITATIONS
73	Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. <i>Genome Medicine</i> , 2014, 6, 43.	3.6	94
74	Pancreatic Adenocarcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1083-1093.	2.3	307
75	Therapeutic Advances in Pancreatic Cancer. <i>Gastroenterology</i> , 2013, 144, 1316-1326.	0.6	257
76	The RON Receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. <i>International Journal of Cancer</i> , 2012, 131, 1744-1754.	2.3	45
77	Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host. <i>Clinical Cancer Research</i> , 2010, 16, 3684-3695.	3.2	83
78	Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers. <i>Cancer Research</i> , 2010, 70, 1130-1140.	0.4	80
79	Preface. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, xv-xvi.	0.6	1
80	Neoadjuvant Therapy for Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1600-1608.	0.9	39
81	The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression. <i>Cancer Research</i> , 2007, 67, 6075-6082.	0.4	108
82	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. <i>Cancer Cell</i> , 2003, 4, 437-450.	7.7	2,150